Send us Feedback

Genitope (GTOP)
Analysis
Data
Financials
QUOTE AND NEWS
MyVax misses the mark: Genitope seems not to notice
Pharma's Cutting Edge  Dec 28  Comment 
Genitope's Webcast   A week ago Genitope reported the results of a pivotal Phase 3 trial for its only clinical candidate, the idiotype-specific, personalized active immunotherapy for Non-Hodgkin's Lymphoma, known as MyVax.  I've been...
Suggest other news sources for this topic
Suggest a News Source
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
Close 
Thanks for your suggestion!
 
RELATED WIKI ARTICLES

Related Articles

more ▼WIKI ANALYSIS
 The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.


You may also be interested in articles related to Genitope (GTOP):

 
TOP CONTRIBUTORS
Sr. Director
Scott Redmond
GTOP AT A GLANCE
 
 
 
 
 
 
 
 
 Genitope (GTOP) primarily fights follicular Non Hogkins Lymphoma via two products. The first is MyVax which is a cancer vaccine. The origin of the vaccine is Dr. Levy from Stanford. Stanford has been vaccinating patients for nearly 3 decades. In that time they have learned that people with a valine valine idiotype are most easily treated and many indatations, though anecdotes, are that such people can be completely curred. The current CEO is Dan Deny, who has been said to be Dr. Levy's favorite student. Currently toward the end of a phase three trial, with fast track FDA approval, the last patient comes in for follow up in November 2007. Data should be available within two months. The second is via a palet of antibiotics. It has been said that in many patients tumor mass can be decreased by 80% or so within only a few weeks. FDA is usually comfortable testing one antibiotic at a time. However with NHL, there are basically 25 expressions of the cell and people have only one type of cell expressed. One antibiotic works per expression.

What makes NHL a reasonable candidate for vaccination is that the cell don't mutate and mutate again. They tend to mutate and make "perfect" replicas on the cancerous cell.




References

Retrieved from "http://www.wikinvest.com/stock/Genitope_(GTOP)"
Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki